REGN – regeneron pharmaceuticals, inc. (US:NASDAQ)

News

Is Regeneron (REGN) Still Attractively Priced After Mixed Recent Share Performance [Yahoo! Finance]
Regeneron Pharmaceuticals (REGN) is now covered by Barclays PLC. They set an "overweight" rating and a $923.00 price target on the stock.
Dupixent Approvals Expand Regeneron's Immunology Reach And Valuation Debate [Yahoo! Finance]
Regeneron Announces Investor Conference Presentation [Yahoo! Finance]
Regeneron Announces Investor Conference Presentation
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com